ReviewFrontiers in cell and developmental biology2025
Single-cell RNA sequencing: new insights for pulmonary endothelial cells.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary endothelial cells (PECs) are indispensable for sustaining lung microenvironmental homeostasis and exert significant influence across a spectrum of pulmonary pathologies. Single-cell RNA sequencing (scRNA-seq) has fundamentally transformed conventional paradigms surrounding PECs, unveiling novel perspectives on their roles in both physiological and pathological lung conditions. This technology provides critical insights into the phenotypic diversity and distinct molecular signatures of PECs, underscoring their substantial heterogeneity in structure, function and gene expression, which is contingent upon their spatial localization within the lung microenvironment. The advancements in scRNA-seq have catalyzed remarkable progress in the therapeutic management of pulmonary pathophysiology, facilitating breakthroughs in the identification of cellular subpopulations, functional characterization and discovery of innovative therapeutic targets. In this review, we systematically synthesize the markers and subclusters of PECs as delineated by scRNA-seq, elucidate their applications in normal and pathological lung contexts, and propose future directions regarding molecular mechanisms and therapeutic interventions targeting PECs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.